A recent study reveals that patients who discontinue blockbuster slimming jabs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who halt traditional lifestyle regimens.
Research printed in a prominent medical journal demonstrates that while obese individuals can lose substantial amounts of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month after stopping.
"Individuals buying such drugs should be informed of the danger of rapid weight regain when the therapy concludes," cautioned researcher Dr. Susan Jebb.
Such speed of recovery suggests a return to original weight within about one and a half years.
Comparing Treatments
The analysis, which examined dozens of trials involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with older methods.
Scientists emphasize that individuals who lose weight through diet and exercise usually see a slower weight regain—approximately 0.1 kg a month—once they finish.
The Reason for the Rapid Regain
Doctors believe the mechanism of the injections explains the amplified weight return.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of GLP-1 levels several times higher than normal may cause the system to produce less of its endogenous hormone, and could reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication results in appetite is unsuppressed, making overeating a significant risk."
An Ongoing Issue?
Health authorities recommend the jabs for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians argue that, given the significant potential of relapse, the therapy is often ongoing.
This opinion is reinforced by drug manufacturers, who say that the results "emphasize the chronic character of excess weight," similar to managing conditions like diabetes.
Patient Accounts
People who have come off the medication describe a sudden return of cravings.
"I experienced a trigger flipping and you're instantly starving," described a patient.
This challenge is compounded if users have not adopted lasting lifestyle or habit modifications during treatment.
Widespread Use
Survey data suggest that millions of adults in the UK have used these injections in the past year, with interest continuing to grow.
- Adoption is more common among females compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
In conclusion, experts emphasize that while these medications are potent agents for weight loss, they are not a standalone fix and maintained weight loss likely depends on combined behavioural changes.